Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism

被引:22
作者
Akizawa, T
Ohashi, Y
Akiba, T
Suzuki, M
Nishizawa, Y
Ogata, E
Slatopolsky, E
Kurokawa, K
机构
[1] Wakayama Med Univ, Ctr Blood Purificat Therapy, Wakayama 6410012, Japan
[2] Univ Tokyo, Sch Hlth Sci & Nursing, Dept Biostat, Tokyo, Japan
[3] Tokyo Womens Med Univ, Kidney Ctr, Div Blood Purificat, Tokyo, Japan
[4] Shinrakuen Hosp, Dept Internal Med, Niigata Soc Serv Org, Social Welf Dept, Niigata, Japan
[5] Osaka City Univ, Grad Sch Med, Dept Metab Endocrinol & Mol Med, Osaka 558, Japan
[6] Fdn Canc Res Hosp, Tokyo, Japan
[7] Washington Univ, Sch Med, Dept Internal Med, Div Renal, St Louis, MO 63110 USA
[8] Tokai Univ, Inst Med Res, Isehara, Kanagawa, Japan
关键词
D O I
10.1111/j.1774-9987.2004.00191.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The dose-response relationships and the safety of administering 22-oxacalcitriol (OCT) to patients with secondary hyperparathyroidism (2HPT) under regular three-times-weekly hemodialysis (HD) were evaluated by double-blind parallel group design. A total of 203 patients with 2HPT were randomly allocated into four groups, and 5 mug (Group L), 10 mug (Group M), or 15 mug (Group H) OCT, or placebo (Group P) was administrated at the end of every HD for 12 weeks. Reductions of intact-parathyroid hormone (iPTH) concentration greater than 30% from baseline were observed in 7.7% of Group P as compared to 77.3% of the pooled OCT groups after 12 weeks of treatment (Mantel test: P<0.001). Time-trends (slopes) of log-iPTH concentration calculated by least-squares line fitting to each patient's data during treatment differed between Group P and the pooled OCT groups (t-test: P < 0.001) and these iPTH slopes decreased dose-dependently (linear trend by t-test: P < 0.001). Slopes of serum calcium corrected for albumin (corrected-sCa) concentrations also differed between Group P and the pooled OCT groups (t-test: P < 0.001), and increased dose-dependently (linear trend by t-test: P < 0.0001). Serum phosphorus and Ca x P product increased significantly only in high dose groups. Slopes of log(iPTH) and corrected-sCa concentrations were reciprocally related. Most adverse events were hypercalcemia and dose-related, but occasionally comprised pruritus or increased serum creatinine phosphokinase. These results indicate that OCT produced a strong and dose-dependent suppression of PTH and an increase of corrected-sCa concentration in patients with 2HPT. The recommended initial dosages of OCT would appear to be 5 mug when pretreatment iPTH concentrations are less than 500 pg/mL, and 10 mug when greater than 500 pg/mL for safe and effective treatment. As in the case of PTH, calcium and phosphorus showed dose-dependent increases. It is therefore essential to take precautions as to possible increases in calcium and phosphorus.
引用
收藏
页码:480 / 491
页数:12
相关论文
共 17 条
  • [1] SYNTHETIC ANALOGS OF VITAMIN-D3 WITH AN OXYGEN ATOM IN THE SIDE-CHAIN SKELETON - A TRAIL OF THE DEVELOPMENT OF VITAMIN-D COMPOUNDS WHICH EXHIBIT POTENT DIFFERENTIATION-INDUCING ACTIVITY WITHOUT INDUCING HYPERCALCEMIA
    ABE, J
    MORIKAWA, M
    MIYAMOTO, K
    KAIHO, SI
    FUKUSHIMA, M
    MIYAURA, C
    ABE, E
    SUDA, T
    NISHII, Y
    [J]. FEBS LETTERS, 1987, 226 (01) : 58 - 62
  • [2] ABE J, 1990, J NUTR SCI VITAMINOL, V36, P21, DOI 10.3177/jnsv.36.21
  • [3] THE NONCALCEMIC ANALOG OF VITAMIN-D, 22-OXACALCITRIOL, SUPPRESSES PARATHYROID-HORMONE SYNTHESIS AND SECRETION
    BROWN, AJ
    RITTER, CR
    FINCH, JL
    MORRISSEY, J
    MARTIN, KJ
    MURAYAMA, E
    NISHII, Y
    SLATOPOLSKY, E
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (03) : 728 - 732
  • [4] 1,25-dihydroxyvitamin D-3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats
    Denda, M
    Finch, J
    Brown, AJ
    Nishii, Y
    Kubodera, N
    Slatopolsky, E
    [J]. KIDNEY INTERNATIONAL, 1996, 50 (01) : 34 - 39
  • [5] ON THE MECHANISMS FOR THE SELECTIVE ACTION OF VITAMIN-D ANALOGS
    DUSSO, AS
    NEGREA, L
    GUNAWARDHANA, S
    LOPEZHILKER, S
    FINCH, J
    MORI, T
    NISHII, Y
    SLATOPOLSKY, E
    BROWN, AJ
    [J]. ENDOCRINOLOGY, 1991, 128 (04) : 1687 - 1692
  • [6] On the evolving nature of understanding dialysis-related disorders
    Eknoyan, G
    Lindberg, JS
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) : S1 - S3
  • [7] REGULATION OF PARATHYROID-HORMONE SYNTHESIS IN CHRONIC-RENAL-FAILURE IN RATS
    FUKAGAWA, M
    KANAME, SY
    IGARASHI, T
    OGATA, E
    KUROKAWA, K
    [J]. KIDNEY INTERNATIONAL, 1991, 39 (05) : 874 - 881
  • [8] Attenuated up-regulation of vitamin D-dependent calcium-binding proteins by 22-oxa-1,25-dihydroxyvitamin D3 in uremic rats:: A possible mechanism for less-calcemic action
    Ichikawa, F
    Hirata, M
    Endo, K
    Katsumata, K
    Ohkawa, H
    Kubodera, N
    Fukagawa, M
    Kurokawa, K
    [J]. NEPHROLOGY, 1998, 4 (5-6) : 391 - 395
  • [9] Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism - A double-blind study among 4 doses
    Koshikawa, S
    Akizawa, T
    Kurokawa, K
    Marumo, F
    Sakai, O
    Arakawa, M
    Morii, H
    Seino, Y
    Ogata, E
    Ohashi, Y
    Akiba, T
    Tsukamoto, Y
    Suzuki, M
    [J]. NEPHRON, 2002, 90 (04): : 413 - 423
  • [10] KUBODERA N, 1992, CHEM PHARM BULL, V40, P1494